What Sayre Therapeutics does
Founded in 2015, Sayre Therapeutics operates in Health Tech offering novel medicines, drug-delivery devices, companion diagnostics and diagnostic imaging agents to various oncologists and rheumatologists. The company focuses on developing small molecules, recombinant proteins, monoclonal antibodies, and diagnostics specifically in Oncology and Immunology. Sayre Therapeutics employs a business model that includes global access and early access programmes, as well as named patient programmes to facilitate product registrations for exclusive distribution in South Asia.
Who runs it
Funding and finances
Why this matters to you: funding stage is a rough proxy for how long the runway is and how much structure to expect. It is not a promise, and a profitable bootstrapped company can be the safer bet.
Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.
Questions and experiences
Nobody has asked anything about Sayre Therapeutics yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.
Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.